Literature DB >> 29584918

Human Immunization With a Polymorphic Malaria Vaccine Candidate Induced Antibodies to Conserved Epitopes That Promote Functional Antibodies to Multiple Parasite Strains.

Gaoqian Feng1,2, Michelle J Boyle1, Nadia Cross1, Jo-Anne Chan1, Linda Reiling1, Faith Osier1,3,4, Danielle I Stanisic5, Ivo Mueller6, Robin F Anders7, James S McCarthy8, Jack S Richards1,2,9, James G Beeson1,2,9.   

Abstract

Background: Overcoming antigenic diversity is a key challenge in the development of effective Plasmodium falciparum malaria vaccines. Strategies that promote the generation of antibodies targeting conserved epitopes of vaccine antigens may provide protection against diverse parasites strains. Understanding differences between vaccine-induced and naturally acquired immunity is important to achieving this goal.
Methods: We analyzed antibodies generated in a phase 1 human vaccine trial, MSP2-C1, which included 2 allelic forms of MSP2, an abundant vaccine antigen on the merozoite surface. Vaccine-induced responses were assessed for functional activity against multiple parasite strains, and cross-reactivity of antibodies was determined using competition ELISA and epitope mapping approaches.
Results: Vaccination induced cytophilic antibody responses with strain-transcending opsonic phagocytosis and complement-fixing function. In contrast to antibodies acquired via natural infection, vaccine-induced antibodies were directed towards conserved epitopes at the C-terminus of MSP2, whereas naturally acquired antibodies mainly targeted polymorphic epitopes. Functional activity of C-terminal-targeted antibodies was confirmed using monoclonal antibodies that promoted opsonic phagocytosis against multiple parasite strains.
Conclusion: Vaccination generated markedly different responses to polymorphic antigens than naturally acquired immunity and targeted conserved functional epitopes. Induction of antibodies targeting conserved regions of malaria antigens provides a promising vaccine strategy to overcome antigenic diversity for developing effective malaria vaccines.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29584918      PMCID: PMC6904323          DOI: 10.1093/infdis/jiy170

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.

Authors:  Christian Flueck; Géraldine Frank; Thomas Smith; Ali Jafarshad; Issa Nebie; Sodiomon B Sirima; Sope Olugbile; Pedro Alonso; Marcel Tanner; Pierre Druilhe; Ingrid Felger; Giampietro Corradin
Journal:  Vaccine       Date:  2009-03-06       Impact factor: 3.641

2.  Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.

Authors:  D E Neafsey; M Juraska; T Bedford; D Benkeser; C Valim; A Griggs; M Lievens; S Abdulla; S Adjei; T Agbenyega; S T Agnandji; P Aide; S Anderson; D Ansong; J J Aponte; K P Asante; P Bejon; A J Birkett; M Bruls; K M Connolly; U D'Alessandro; C Dobaño; S Gesase; B Greenwood; J Grimsby; H Tinto; M J Hamel; I Hoffman; P Kamthunzi; S Kariuki; P G Kremsner; A Leach; B Lell; N J Lennon; J Lusingu; K Marsh; F Martinson; J T Molel; E L Moss; P Njuguna; C F Ockenhouse; B Ragama Ogutu; W Otieno; L Otieno; K Otieno; S Owusu-Agyei; D J Park; K Pellé; D Robbins; C Russ; E M Ryan; J Sacarlal; B Sogoloff; H Sorgho; M Tanner; T Theander; I Valea; S K Volkman; Q Yu; D Lapierre; B W Birren; P B Gilbert; D F Wirth
Journal:  N Engl J Med       Date:  2015-10-21       Impact factor: 91.245

3.  Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum.

Authors:  Paul R Gilson; Thomas Nebl; Damjan Vukcevic; Robert L Moritz; Tobias Sargeant; Terence P Speed; Louis Schofield; Brendan S Crabb
Journal:  Mol Cell Proteomics       Date:  2006-04-07       Impact factor: 5.911

4.  Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies.

Authors:  Charlotte Joos; Laurence Marrama; Hannah E J Polson; Sandra Corre; Antoine-Marie Diatta; Babacar Diouf; Jean-François Trape; Adama Tall; Shirley Longacre; Ronald Perraut
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

5.  Antigenic characterization of an intrinsically unstructured protein, Plasmodium falciparum merozoite surface protein 2.

Authors:  Christopher G Adda; Christopher A MacRaild; Linda Reiling; Kaye Wycherley; Michelle J Boyle; Vivian Kienzle; Paul Masendycz; Michael Foley; James G Beeson; Raymond S Norton; Robin F Anders
Journal:  Infect Immun       Date:  2012-09-10       Impact factor: 3.441

6.  The risk of malarial infections and disease in Papua New Guinean children.

Authors:  Pascal Michon; Jennifer L Cole-Tobian; Elijah Dabod; Sonja Schoepflin; Jennifer Igu; Melinda Susapu; Nandao Tarongka; Peter A Zimmerman; John C Reeder; James G Beeson; Louis Schofield; Christopher L King; Ivo Mueller
Journal:  Am J Trop Med Hyg       Date:  2007-06       Impact factor: 2.345

7.  A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.

Authors:  James S McCarthy; Joanne Marjason; Suzanne Elliott; Paul Fahey; Gilles Bang; Elissa Malkin; Eveline Tierney; Hayley Aked-Hurditch; Christopher Adda; Nadia Cross; Jack S Richards; Freya J I Fowkes; Michelle J Boyle; Carole Long; Pierre Druilhe; James G Beeson; Robin F Anders
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

8.  Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.

Authors:  Bankala Krishnarjuna; Dean Andrew; Christopher A MacRaild; Rodrigo A V Morales; James G Beeson; Robin F Anders; Jack S Richards; Raymond S Norton
Journal:  Sci Rep       Date:  2016-02-11       Impact factor: 4.379

9.  Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.

Authors:  Damien R Drew; Anthony N Hodder; Danny W Wilson; Michael Foley; Ivo Mueller; Peter M Siba; Arlene E Dent; Alan F Cowman; James G Beeson
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

10.  A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens.

Authors:  Damien R Drew; Danny W Wilson; Salenna R Elliott; Nadia Cross; Ulrich Terheggen; Anthony N Hodder; Peter M Siba; Kiprotich Chelimo; Arlene E Dent; James W Kazura; Ivo Mueller; James G Beeson
Journal:  BMC Med       Date:  2016-09-23       Impact factor: 8.775

View more
  14 in total

1.  Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.

Authors:  Antje Blank; Kristin Fürle; Anja Jäschke; Michael Lanzer; Walter E Haefeli; Hermann Bujard; Gerd Mikus; Monika Lehmann; Johannes Hüsing; Kirsten Heiss; Thomas Giese; Darrick Carter; Ernst Böhnlein
Journal:  NPJ Vaccines       Date:  2020-01-31       Impact factor: 7.344

Review 2.  Subdominance in Antibody Responses: Implications for Vaccine Development.

Authors:  Gunnar Lindahl
Journal:  Microbiol Mol Biol Rev       Date:  2020-11-25       Impact factor: 11.056

3.  Age-dependent changes in circulating Tfh cells influence development of functional malaria antibodies in children.

Authors:  Jo-Anne Chan; Jessica R Loughland; Lauren de la Parte; Satomi Okano; Isaac Ssewanyana; Mayimuna Nalubega; Felistas Nankya; Kenneth Musinguzi; John Rek; Emmanuel Arinaitwe; Peta Tipping; Peter Bourke; Dean Andrew; Nicholas Dooley; Arya SheelaNair; Bruce D Wines; P Mark Hogarth; James G Beeson; Bryan Greenhouse; Grant Dorsey; Moses Kamya; Gunter Hartel; Gabriela Minigo; Margaret Feeney; Prasanna Jagannathan; Michelle J Boyle
Journal:  Nat Commun       Date:  2022-07-18       Impact factor: 17.694

4.  B cell clonal expansion and mutation in the immunoglobulin heavy chain variable domain in response to Pfs230 and Pfs25 malaria vaccines.

Authors:  Camila H Coelho; Jacob D Galson; Johannes Trück; Patrick E Duffy
Journal:  Int J Parasitol       Date:  2021-12-09       Impact factor: 4.330

5.  Immunization with merozoite surface protein 2 fused to a Plasmodium-specific carrier protein elicits strain-specific and strain-transcending, opsonizing antibody.

Authors:  Jacqueline S Eacret; Donna M Gonzales; Raymond G Franks; James M Burns
Journal:  Sci Rep       Date:  2019-06-21       Impact factor: 4.996

6.  Targets of complement-fixing antibodies in protective immunity against malaria in children.

Authors:  Linda Reiling; Michelle J Boyle; Michael T White; Danny W Wilson; Gaoqian Feng; Rupert Weaver; D Herbert Opi; Kristina E M Persson; Jack S Richards; Peter M Siba; Freya J I Fowkes; Eizo Takashima; Takafumi Tsuboi; Ivo Mueller; James G Beeson
Journal:  Nat Commun       Date:  2019-02-05       Impact factor: 14.919

7.  Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia.

Authors:  Damian A Oyong; Enny Kenangalem; Jeanne R Poespoprodjo; James G Beeson; Nicholas M Anstey; Ric N Price; Michelle J Boyle
Journal:  JCI Insight       Date:  2018-11-15

Review 8.  Complement in malaria immunity and vaccines.

Authors:  Liriye Kurtovic; Michelle J Boyle; D Herbert Opi; Alexander T Kennedy; Wai-Hong Tham; Linda Reiling; Jo-Anne Chan; James G Beeson
Journal:  Immunol Rev       Date:  2019-09-26       Impact factor: 12.988

9.  Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.

Authors:  Antje Blank; Kristin Fürle; Anja Jäschke; Michael Lanzer; Walter E Haefeli; Hermann Bujard; Gerd Mikus; Monika Lehmann; Johannes Hüsing; Kirsten Heiss; Thomas Giese; Darrick Carter; Ernst Böhnlein
Journal:  NPJ Vaccines       Date:  2020-01-31       Impact factor: 7.344

10.  Characterization of drug resistance and genetic diversity of Plasmodium falciparum parasites from Tripura, Northeast India.

Authors:  S J Patgiri; K Sarma; N Sarmah; N Bhattacharyya; D K Sarma; T Nirmolia; D R Bhattacharyya; P K Mohapatra; D Bansal; P K Bharti; R Sehgal; J Mahanta; A A Sultan
Journal:  Sci Rep       Date:  2019-09-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.